Fosamax and Osteonecrosis of the Jaw: Causation, Risk, and What Studies Show

Latest update (2026-05)

FDA enforcement record (Ongoing): This recall is being conducted due to out of specification assay results in a limited number of bottles that were stored on side. [source]

From General Health Information to Specific Exposure Concerns

The legacy of general health and science information has long served as a foundation for public understanding of medical risks and therapeutic benefits. Within this broad context, discussions of pharmaceutical interventions have historically emphasized their intended outcomes, such as the management of bone density disorders. This heritage provides a necessary baseline for evaluating how medications interact with biological systems over time. As inquiry deepens, attention naturally shifts from broad health principles to specific exposure scenarios. In the domain of mass production, the focus moves beyond patient populations to occupational settings where sustained contact with pharmaceutical compounds may occur. The transition from general health discourse to occupational exposure concern requires examining how manufacturing processes, handling protocols, and environmental controls influence risk profiles. This pivot acknowledges that while clinical use of medications like bisphosphonates has been studied extensively, the implications for workers involved in their production present distinct considerations. The occupational lens introduces variables such as duration of exposure, concentration levels, and protective measures that differ from therapeutic administration. By bridging from general health information to this specialized context, we can better frame the questions surrounding exposure risks without prematurely attributing specific outcomes. This approach maintains analytical rigor while expanding the scope of relevant inquiry.

Bridging to Fosamax and Osteonecrosis of the Jaw

Building on the foundation of general health information, we now focus specifically on Fosamax (alendronate), a bisphosphonate medication approved for the treatment and prevention of osteoporosis in postmenopausal women, treatment to increase bone mass in men with osteoporosis, treatment of glucocorticoid-induced osteoporosis, and treatment of Paget's disease of bone (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Osteonecrosis of the jaw (ONJ) is a recognized adverse effect associated with bisphosphonate use, including Fosamax. ONJ involves necrotic bone exposure in the maxillofacial region, often presenting with delayed healing after dental procedures, local infection, or occurring spontaneously (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Clinical diagnosis typically requires visualization of exposed bone in the jaw that persists for more than eight weeks, with no history of radiation therapy to the jaws. The pharmacology of Fosamax involves inhibition of osteoclast-mediated bone resorption, which reduces bone turnover. This mechanism, while beneficial for increasing bone mass and reducing fracture risk, can impair normal bone remodeling and repair processes in the jaw. Multiscale characterization of jawbone tissue has provided insights into how the jawbone responds to bisphosphonate therapy, helping to understand the development of bisphosphonate-related ONJ (https://pubmed.ncbi.nlm.nih.gov/40345077/). The jawbone's high remodeling rate and susceptibility to microdamage may make it particularly vulnerable to the suppressive effects of bisphosphonates on osteoclast activity.

Evidence of Risk and Causation

Reported adverse effects in Fosamax labeling explicitly include ONJ. The time to onset of ONJ symptoms can vary from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). In placebo-controlled clinical studies of Fosamax, the percentages of patients with jaw symptoms were similar in the Fosamax and placebo groups, suggesting that ONJ is a rare event in clinical trial populations (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). However, post-marketing surveillance has identified ONJ cases in patients taking bisphosphonates, including Fosamax. Known risk factors for ONJ include invasive dental procedures (e.g., tooth extraction, dental implants, boney surgery), diagnosis of cancer, concomitant therapies (e.g., chemotherapy, corticosteroids, angiogenesis inhibitors), poor oral hygiene, and co-morbid disorders such as periodontal disease, anemia, coagulopathy, infection, and ill-fitting dentures (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The risk of ONJ may increase with longer duration of bisphosphonate exposure (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). Adequacy of warnings regarding Fosamax and ONJ is addressed in the drug labeling. The warnings and precautions section for Fosamax includes a specific subsection on ONJ, describing the condition, associated risk factors, and recommendations for management (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). The labeling advises discontinuation of Fosamax if severe symptoms develop, noting that most patients had relief of symptoms after stopping, though a subset experienced recurrence when rechallenged with the same drug or another bisphosphonate (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). For patients requiring invasive dental procedures, discontinuation of bisphosphonate treatment may reduce the risk for ONJ (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10307e7e-9a84-4aa1-8c5c-4b209cffe4d1). The labeling also notes that the optimal duration of Fosamax use has not been determined, and for patients at low risk for fracture, drug discontinuation after 3 to 5 years may be considered (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Causation-related considerations for affected patients involve evaluating the temporal relationship between Fosamax exposure and ONJ onset. The timeline between exposure and documented harm can vary widely, from one day to several months after starting the drug (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). A cohort study among female patients treated for osteoporosis in the United Kingdom Clinical Practice Research Datalink found that ONJ risk was threefold higher after 2-3 years of treatment and eightfold higher after 10 years compared with past use (https://pubmed.ncbi.nlm.nih.gov/39400702/). Absolute risks remained low, approximately 0.05% after 5 years, and diminished after discontinuation of treatment (https://pubmed.ncbi.nlm.nih.gov/39400702/). This study provides evidence of a dose-response relationship, with longer exposure associated with greater risk, supporting a causal link. Additionally, the recurrence of symptoms upon rechallenge with bisphosphonates in some patients further suggests a causal role (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56). Mechanistic pathways linking Fosamax to ONJ involve the drug's suppression of bone turnover, which can impair the jawbone's ability to repair microdamage and respond to local infections or trauma. The jawbone's unique characteristics, as elucidated by multiscale characterization, may predispose it to this adverse effect (https://pubmed.ncbi.nlm.nih.gov/40345077/). The presence of concomitant risk factors, such as dental procedures or corticosteroid use, can further increase susceptibility. In summary, while ONJ is a rare adverse effect of Fosamax, the evidence from labeling, epidemiological studies, and mechanistic research supports a causal association, with risk increasing with longer duration of use and in the presence of additional risk factors.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is Fosamax and how is it related to osteonecrosis of the jaw?

Fosamax (alendronate) is a bisphosphonate medication used to treat osteoporosis and other bone conditions. Osteonecrosis of the jaw (ONJ) is a rare but recognized adverse effect associated with bisphosphonate use, including Fosamax. ONJ involves necrotic bone exposure in the jaw, often after dental procedures or spontaneously. The drug's suppression of bone turnover can impair jawbone repair, contributing to ONJ risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14e931fd-2c5f-4d90-b7db-5980706f4a56).

What does the research show about the risk of ONJ from Fosamax?

Research indicates that ONJ risk increases with longer duration of Fosamax use. A cohort study found a threefold higher risk after 2-3 years and an eightfold higher risk after 10 years compared to past use, though absolute risks remain low (about 0.05% after 5 years). Risk diminishes after discontinuation. Additional risk factors include dental procedures, cancer, corticosteroids, and poor oral hygiene (https://pubmed.ncbi.nlm.nih.gov/39400702/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Fosamax exposure and a confirmed Osteonecrosis of the Jaw diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.